The Patent Finder

Orionis Biosciences B.V.

29 patents currently held · Updated Nov 18, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for Chimeric Protein Comprising an Interferon Alpha 2MUTANT and a PD-L1 Binding Moiety (US 11,661,455) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
  • 1 fee due Jan 18, 2027
    The maintenance fee for Bi-Functional Chimeric Proteins and Uses Thereof (US 11,702,477) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
  • 1 fee due Mar 12, 2027
    The maintenance fee for Therapeutic Targeting of Non-Cellular Structures (US 11,753,463) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
  • 1 fee due Aug 13, 2027
    The maintenance fee for Fibroblast Binding Agents and Use Thereof (US 11,896,643) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 11,702,477Bi-Functional Chimeric Proteins and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,988,538Bispecific Signaling Agents and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,384,154Targeted Chimeric Proteins and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,753,463Therapeutic Targeting of Non-Cellular Structures
In force
 · High confidence
In forceHigh confidence
US 11,084,859Targeted Mutant Interferon-Gamma and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,522,641Targeted Mutant Interferon-Gamma and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,661,455Chimeric Protein Comprising an Interferon Alpha 2MUTANT and a PD-L1 Binding Moiety
In force
 · High confidence
In forceHigh confidence
US 11,236,141Targeted Mutant Interferon-Beta and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,497,436Chimeric Protein, and Encoding Nucleic Acid Thereof, Comprising Interferon-Beta and a Targeting Moiety Comprising a Single-Domain Antibody or Single-Chain Antibody
In force
 · Medium confidence
In forceMedium confidence
US 11,001,631CLEC9A Binding Agents
In force
 · High confidence
In forceHigh confidence
10 of 29 patents shown.
Pro members see all 29.
Pro members: see all 29 patents
Also on record, not counted in the 29: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

16 pending · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited